Merck MS Drug Fails to Meet Target of Late-Stage Trials : vi

By David Sachs


Merck's multiple sclerosis drug evobrutinib didn't meet a key goal in late-stage trials.

The German pharmaceutical company's phase 3 clinical trials for the drug did not...

Related Keywords

Germany , German , David Sachs , , Danny Bar Zohar , Dow Jones , Markets ,